HOME >> MEDICINE >> NEWS
Studies Look At Threshold Effect Of Cholesterol-Lowering "Statin" Drugs

DALLAS, April 21 -- Do individuals gain progressive benefits in heart attack protection as the drugs, called statins, take cholesterol levels to "new lows?" This is the topic of three reports and an editorial appearing in today's Circulation: Journal of the American Heart Association.

"An important question is how much additional benefit do individuals who have had a heart attack get from reducing their low-density lipoprotein, (LDL), or 'bad' cholesterol levels from low to very low levels, (below the recommended 100 milligrams/deciliter)? Is it considerable, small amounts or none?" asks Scott M. Grundy, M.D., Ph.D., who wrote an accompanying editorial in Circulation. He is director of the center for human nutrition at the University of Texas Southwestern Medical Center in Dallas.

In one report researchers found that the benefits of the popular statin drugs -- shown to sharply reduce heart attack risk in individuals with elevated blood levels of cholesterol -- taper off, indicating a "threshold" effect when LDL reaches 125 mg/dL, according to Frank M. Sacks, M.D., associate professor of medicine, and other researchers at Brigham and Women's Hospital and Harvard Medical School, Boston.

Another report in the same issue however suggested continued benefit down to a level of 100 mg/dL, although there was some lessening of benefit as LDL approached the lower levels.

Even though the data suggest that there may be attenuation in the benefit of cholesterol lowering below 125 mg/dL, Grundy stresses that these reports should not be taken as the final word on the issue. "For the present, the guidelines by the National Cholesterol Education Program (NCEP), endorsed by the American Heart Association, offer the most reliable basis for physicians' decisions regardless of the optimal lower limit for LDL cholesterol," says Grundy. A new statin trial, the Treating to New Target (TNT) study, should provide the answers concerning lower limit of benefit, but
'"/>

Contact: Carole Bullock
caroleb@amhrt.org
214-706-1279
American Heart Association
20-Apr-1998


Page: 1 2 3 4 5

Related medicine news :

1. Studies underscore genetic involvement in nicotine addiction & aggressive hostility
2. Studies address issues of risk and survival in rapidly increasing GI cancers
3. Studies examine coffee drinking and risk of liver and colorectal cancers
4. Studies reveal physicians attitudes on end-of-life care
5. Studies from the November issue of The Archives of Dermatology, a theme issue on facial rejuvenation
6. Studies link obesity to increased frequency of heartburn symptoms; greater risk of esophageal cancer
7. Studies demonstrate positive data in treatment of hepatitis C
8. Studies examine risk factors and potential consequences associated with prehypertension
9. Studies show ACTOS(R) (pioglitazone HCl) has positive effects on various components of dyslipidemia
10. Studies identify risk factors for colon cancer
11. Studies indicate healthy eating may affect cancer development, improve digestive system

Post Your Comments:
(Date:2/26/2015)... 2015 marks five years of being ... Caggiano! , Orthodontics is a perfect blend of ... background in biomedical engineering, his artistic talent, his extensive ... dentist allows Dr. Caggiano to create innovative approaches to ... named Orthodontic Products’ Best of 2012, a national recognition, ...
(Date:2/26/2015)... The hip resurfacing procedure at Texas Orthopedics has ... Short to resume his active lifestyle, it has improved his ... Kilimanjaro, the highest free-standing mountain in the world, in an ... late 20s, Short suffered from early onset degeneration. His condition ... bone on bone. , Then about five years ago, ...
(Date:2/26/2015)... CA (PRWEB) February 26, 2015 Beckman ... “Diversity of extracellular vesicles and their cargo in cell-to-cell ... vesicles and their relevance for cell-to-cell communication. The webinar ... March 4, 2015 at 8:00am PT. , Every cell ... extracellular vesicles (EVs) , often called “exosomes” or “microvesicles.” ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 2015 ... is a professional and in-depth study on the ... with a focus on the Chinese situation. ... are Lawton Gmbh & Co.KG, Hu-Friedy, Medisporex, Towne ... Instruments, Shuangyin, Shanghai Weirong Medical Equipment, Shuanglu, Changshu ...
(Date:2/26/2015)... 26, 2015 “ KnowNote ” was featured ... the latest and coolest mobile applications on the iOS, Android, ... host of NewsWatch, conducted the app review and shared with ... in rhythm and in tune. , Learning a musical instrument ... But what if people could take something they already know ...
Breaking Medicine News(10 mins):Health News:Dr. David Caggiano of Caggiano Orthodontics is Celebrating Five Years as an "NJ Top Dentist" ! 2Health News:Dr. David Caggiano of Caggiano Orthodontics is Celebrating Five Years as an "NJ Top Dentist" ! 3Health News:Hip Resurfacing at Texas Orthopedics Enables Patient to Climb Mt. Kilimanjaro 2Health News:Hip Resurfacing at Texas Orthopedics Enables Patient to Climb Mt. Kilimanjaro 3Health News:Beckman Coulter Webinar Series Presents Diversity of Extracellular Vesicles and Their Cargo in Cell-to-cell Communication 2Health News:Beckman Coulter Webinar Series Presents Diversity of Extracellular Vesicles and Their Cargo in Cell-to-cell Communication 3Health News:Global Hemostat Industry Data, Size and Growth Report 2015-2020 Now Available at DeepResearchReports.com 2Health News:Global Hemostat Industry Data, Size and Growth Report 2015-2020 Now Available at DeepResearchReports.com 3Health News:A Modern Way to Learn Music was Featured on NewsWatch Television on January 30, 2015 2
(Date:2/26/2015)... -- ABIVAX, a clinical stage biotech company developing ... it has dosed in New Zealand ... ABX203 which is taking place in several countries of the ... to assess whether ABX203 can deliver a significant improvement in ... load for a much longer period of time when compared ...
(Date:2/26/2015)... Medtronic, Inc. (U.S.), St. Jude Medical, ... in the Saudi Arabia , ... expected to lead the market during the period of 2014 ... player in the market, and owns a wide product portfolio ... Entera Neurostimulator are some of the most popular brands of ...
(Date:2/26/2015)... --  HeartWare International, Inc . (NASDAQ: HTWR ... support technologies that are revolutionizing the treatment of advanced ... the fourth quarter ended December 31, 2014, a 38% ... same period of 2013.  For the fiscal year 2014, ... increase compared to revenue of $207.9 million in 2013.  ...
Breaking Medicine Technology:ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 2ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 3ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 4ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 5Middle East & Africa Internal Neurostimulation/Neuromodulation Market is Expected to Reach $6.1 Million by 2019, at a CAGR of 17.9% from 2014 to 2019 2Middle East & Africa Internal Neurostimulation/Neuromodulation Market is Expected to Reach $6.1 Million by 2019, at a CAGR of 17.9% from 2014 to 2019 3Middle East & Africa Internal Neurostimulation/Neuromodulation Market is Expected to Reach $6.1 Million by 2019, at a CAGR of 17.9% from 2014 to 2019 4HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 2HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 3HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 4HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 5HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 6HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 7HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 8HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 9HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 10HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 11HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 12
Cached News: